New combo therapy for bile duct disease moves to Long-Term safety check
NCT ID NCT06755541
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This study looks at the long-term safety of taking fenofibrate together with ursodeoxycholic acid for people with primary biliary cholangitis (PBC), a chronic liver disease. About 150 adults who have already completed a previous fenofibrate study will take the combination and be monitored for side effects, liver function, and need for transplant. The goal is to see if this treatment is safe enough to control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.